MarketBeat
22 Nov 2026, 12:13 UTC · 1h ago
Hikma Pharmaceuticals Confident on 2026 Targets Despite Flat Injectables Sales
Impact · against what's priced in
Hikma's confidence in 2026 targets and a significant new contract manufacturing deal offset a disappointment in injectables growth. The defined leadership transition window for the CEO adds a layer of medium-term uncertainty to the valuation.
- HIK+0.20
No priced-in read yet
- In context
A major contract manufacturing deal for the Columbus facility and the expected 2027 ramp-up of TYZAVAN provide tangible growth catalysts, though these are partially tempered by flat injectables sales and a fixed CEO transition window through 2028.
Read from the article alone





